ArticleClinical and translational science2026
The Australian Public's Awareness, Knowledge and Perspectives Towards Pharmacogenomics: A Nationwide Survey, and Semi-Structured Interviews.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pharmacogenomics has the potential to improve medication responses for the public; however, its adoption in clinical practice has been slow. Consumer representation and engagement are crucial for pharmacogenomics implementation, since it is their data that is central to testing. This study investigated the Australian public's awareness, knowledge, and perceptions of pharmacogenomics via a mixed-methods approach. Firstly, a cross-sectional survey with a nationally representative sample of 772 members of the Australian general public assessed the frequency of pharmacogenomics awareness, knowledge, perceived benefit and concern. Subsequent semi-structured interviews with 21 members of the Australian public provided deeper insights into perceptions through thematic analysis. Over three-quarters (76.3%) of participants were unaware of pharmacogenomics, while 6.2% categorized themselves as aware and knowledgeable about the topic. Interviews found five major themes: (1) Knowledge and Understanding, (2) Trust, (3) Personalized and Holistic Care, (4) Clinical Utility, and (5) Accessibility. Overall, participants highlighted several key steps for pharmacogenomics integration into clinical practice and to increase awareness. These include the importance of simplifying the terminology, providing education and transparency to overcome apprehension, addressing cost concerns, communicating the value clearly and increasing community engagement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.